Skip to content
Open access

Towards a deep-learning genomic tool for risk stratification and diagnostic support in sporadic ALS

Sep 2026 · Genome Medicine · 0 citations

TL;DR

A new model is developed that is validated across diverse ALS populations, can handle discrepancies between genotyping technologies, and is applicable to individual external samples, and has the potential to extend genetic risk assessment to all individuals, regardless of their family history or the presence of known ALS mutations.

Abstract

A variety of common and rare genetic factors have been implicated in the development of amyotrophic lateral sclerosis (ALS), and the evidence is that a genetic component is present in most affected individuals. However, our current understanding of ALS genetics causally explains only a small proportion of sporadic ALS, which accounts for over 90% of all people with ALS. This limits the utility of genetic testing in screening, diagnosis and management to the 15–20% of people with ALS who carry a known pathogenic variant. Capsule Networks (CapsNets) constitute a deep learning method that has demonstrated strong performance in using genotyping data to predict individuals at risk for ALS. However, their use is constrained by a lack of generalised, flexible, and externally validated implementations across comprehensive datasets that account for the technical, biological, and clinical heterogeneity found in real-world disease scenarios. In this study, we build upon this method to address existing limitations using large-scale datasets from over 47,000 individuals from 13 countries, genotyped with nine different genotyping platforms. We developed a new model that is validated across diverse ALS populations, can handle discrepancies between genotyping technologies, and is applicable to individual external samples. Our model achieved high precision and sensitivity in distinguishing between individuals with ALS and non-affected controls. Moreover, in simulations of population screening for ALS, its predictive performance under a simulated population screening scenario was comparable to published estimates for screening based on major ALS-causing mutations, such as FUS and C9orf72 . Our results demonstrate that this flexible and externally validated method could support genetic risk stratification and, following further prospective clinical validation, future diagnostic support in sporadic ALS. Complementing current genetic testing approaches based on known ALS mutations, it has the potential to extend genetic risk assessment to all individuals, regardless of their family history or the presence of known ALS mutations.

Read PDF

Similar papers

#explainable ai Open access Sep 2026

End-to-end deep learning methods for genetic risk prediction of schizophrenia

It is shown that explainable neural networks improve genetic prediction of schizophrenia by capturing genetic interactions, and nonlinear neural networks significantly outperform conventional additive models when sufficient sample size is available.

N. Verplaetse, Y. Moreau, D. Raimondi · 0 citations
Open access Aug 2026

Machine Learning approaches for the detection of disease-causing variants in whole-genome data need to address the expression of functional genes

A benchmark is constructed that includes real data and synthetic data with known generating mechanisms and various dataset sizes and levels of noise, and shows that it is necessary to take into account the expression of functional genes in order to successfully predict disease.

Camilla Mapstone, Julia Handl, David Talavera · 0 citations
Open access Aug 2026

Deep DNA and protein level feature integration for robust clinical variant interpretation using probabilistic gradient boosting

A probabilistic gradient boosting model on variant pathogenicity prediction that applies biological characteristics at both level of DNA and protein levels while also scaling the level of uncertainty in clinical decision making is presented.

Karthik V, S. Prejesh, Sumedh Deepak Kudale et al. · 0 citations
Open access Sep 2026

Alzheimer’s disease diagnosis based on gene selection and cross-tissue validation

Background Early and accurate diagnosis is critical for intervening in the progression of Alzheimer’s disease (AD). However, traditional clinical diagnostic techniques, such as invasive cerebrospinal fluid punctures and expensive neuroimaging, struggle to meet the demands of large-scale early screening. Methods This st...

Xiao-Lan Zhang, Xiao-Tong Tang, Qian Bo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.